---
schema_version: "secwatch.filing_event.v1"
accession: "0001725160-24-000120"
form_type: "8-K"
ticker: "ZNTL"
cik: "0001725160"
company_name: "Zentalis Pharmaceuticals, Inc."
filed_at: "2024-05-29T23:59:59+00:00"
generated_at: "2026-06-01T07:42:49.611121+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# Zentalis appoints Luke Walker, M.D. to board, expanding to 7 directors

## Summary
- Board increased from 6 to 7 members; Dr. Walker appointed as Class II director effective May 24, 2024.
- Term runs until 2025 annual meeting; Dr. Walker also joins Audit Committee.
- Initial RSU grant of 72,481 shares valued at $850,000, vesting over 3 years.
- Annual retainer for board service $45,000 plus $10,000 for Audit Committee membership.
- Standard indemnification agreement signed; annual equity grants after 6 months service.

## SEC filing metadata
- accession: 0001725160-24-000120
- form_type: 8-K
- ticker: ZNTL
- cik: 0001725160
- company_name: Zentalis Pharmaceuticals, Inc.
- filed_at: 2024-05-29T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1725160/000172516024000120/0001725160-24-000120-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1725160/000172516024000120/zntl-20240524.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001725160-24-000120
- JSON: https://secwatch.observer/filing/0001725160-24-000120.json
- Plain text: https://secwatch.observer/filing/0001725160-24-000120.txt

## Key facts
- Executive change
  Luke Walker, M.D. was appointed as Director at Zentalis Pharmaceuticals, Inc..
  - Action: appointed
  - Role: Director
  source text: On and effective May 24, 2024, the Board of Directors (the “Board”) of Zentalis Pharmaceuticals, Inc. (the “Company”) increased its size from six to seven directors and appointed Luke Walker, M.D., as a Class II director.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1725160/000172516024000120/0001725160-24-000120-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.